Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia

Perazzo, Hugo; Munteanu, Mona; Ngo, Yen; Lebray, Pascal; Seurat, N.; Rutka, F.; Couteau, M.; Jacqueminet, S.; Giral, Philippe; Monneret, Denis; Imbert‐Bismut, Françoise; Ratziu, Vlad; Hartemann-Huertier, A; Housset, Chantal; Poynard, Thierry

doi:10.1111/apt.12946

Cited by 30 publications

(27 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We confirmed our previous results in type 2‐diabetes, that FibroTest predicted cardiovascular events, and improved the Framingham‐risk score . For the first time we observed that FibroTest was also predictive of cardiovascular‐related deaths, both in NAFLD patients with and without diabetes and also among CHC patients.…”

Section: Discussionsupporting

confidence: 89%

“…This could be due to the natural history of NAFLD, with lower incidence of liver‐related death and higher non‐liver‐related causes of mortality in comparison with the viral or alcoholic liver diseases. In a study of FibroTest in 2312 patients with type 2 diabetes or dyslipidemias, we found a significant prognostic value of FibroTest, for the overall survival . In type 2 diabetes, FibroTest predicted cardiovascular events and improved the Framingham‐risk score.…”

Section: Introductionmentioning

confidence: 79%

“…The first strength was the sample size and the long‐term follow‐up, which permitted to analyse a total of 240 deaths in the NAFLD group including 38 liver‐related deaths, much more than in our previous study in two different cohorts which analysed 172 deaths with only seven liver‐related deaths . The only other long‐term prognostic study published included 360 patients with NAFLD and analysed 83 deaths with 17 liver‐related deaths .…”

Section: Discussionmentioning

confidence: 99%

“…First, we have not performed an external validation. However, the prognostic value of FibroTest in NAFLD was already validated for overall survival and the risk of cardiovascular events in diabetic patients of the FibroFrance project, and its diagnostic performance has been extensively validated in NAFLD patients…”

Section: Discussionmentioning

confidence: 99%

“…In a study of FibroTest in 2312 patients with type 2 diabetes or dyslipidemias, we found a significant prognostic value of FibroTest, for the overall survival. 9 In type 2 diabetes, FibroTest predicted cardiovascular events and improved the Framingham-risk score. For the prediction of liver-related death the number of events at 10 years was too small (n = 7) for any conclusion.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease

Munteanu

Pais

Peta

et al. 2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

SummaryBackgroundAlthough the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non‐alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the prediction of liver‐related death.AimTo validate the 10‐year prognostic value of FibroTest in NAFLD for the prediction of liver‐related death.MethodPatients in the prospective FibroFrance cohort who underwent a FibroTest between 1997 and 2012 were pre‐included. Mortality status was obtained from physicians, hospitals or the national register. Survival analyses were based on univariate (Kaplan‐Meier, log rank, AUROC) and multivariate Cox risk ratio taking into account age, sex and response to anti‐viral treatment as covariates. The comparator was the performance of the FibroTest in CHC, the most validated population.Results7082 patients were included; 1079, 3449, 2051, and 503 with NAFLD, CHC, CHB, and ALD, respectively. Median (range) follow‐up was 6.0 years (0.1‐19.3). Ten year survival (95% CI) without liver‐related death in patients with NAFLD was 0.956 (0.940‐0.971; 38 events) and 0.832 (0.818‐0.847; 226 events; P = 0.004) in CHC. The prognostic value (AUROC / Cox risk ratio) of FibroTest in patients with NAFLD was 0.941 (0.905‐0.978)/1638 (342‐7839) and even higher than in patients with CHC 0.875 (0.849‐0.901; P = 0.01)/2657 (993‐6586).ConclusionsThe FibroTest has a high prognostic value in NAFLD for the prediction of liver‐related death. (ClinicalTrials.gov number, NCT01927133).

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Introductionmentioning

confidence: 79%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations